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Introduction
Breast cancer is the second most common type of
cancer and the second leading cause of cancer-related
deaths (1). RNA interference (RNAi) is a eukaryotic
cellular pathway in which a short strand of RNA is able
to induce the degradation of its mRNA complementary
sequence and decrease the expression of that gene
(1,3,5). RNA interference can be applied to therapeutics
in which siRNA can be synthetically produced which are
capable of cancer gene-specific knockdown (1,5).
Naked siRNA is subject to degradation and removal
by enzymes (3,5,6). It is also too large and too
negatively charged to cross cellular membranes due to
its strong anionic charge of the phosphate repelling the
anionic charge of a cells membrane surface(3-6).
Therefore a safe and effective system of delivery must
be developed in order to facilitate transfection and
artificially induce RNAi. Nanocarriers synthesized from
polymers such as poly lactic co-glycolic acid (PLGA)
have been shown to control release, protect its contents,
remain stable, and can be modified for targeted delivery
(2,4).
If administered systemically, the particles must be
able to target the cells or tissue while avoiding uptake by
non-target tissues, kidney filtration, and degradation by
phagocytes and enzymes (3,4). Active targeting of the
tissue may be incorporated into the mode of delivery
which can assist in in vivo biodistribution and delivery
(3). Some tumors allow the entry of larger molecules, up
to 200nm in diameter, which can accommodate drug
delivery nanoparticles through passive targeting (3).
Therefore, appropriate and efficient delivery remains one
of the biggest challenges in the development of siRNA
as an anti-cancer treatment
Hypothesis
It was hypothesized that the tumor targeting
peptides would effectively penetrate the cell and
transfect our particles. Subsequently, gene silencing was
expected to be observed in the transfected cells.
Experimental Methods
Cell Culture
MCF7 cells were grown in RPMI media containing L-Glu,
non-essential amino acids, penicillin/streptomycin, and
10% FBS at 37°C. Cells were plated (10,000 to 20,000
cells/well) on a 96-well plate in 200ul of media with
serum. Cells were plated 20-24 hours in advance.
Nanoparticle Preparation/Peptide Conjugation
Nanoparticles were composed of 1:10 PLGA-
PEG:PLGA-PEG-Mal in 2% PVA solution. Double
emulsion was done using DCM. The particles were sized
and the PVA supernatant was used to measure
entrapment efficiency. Peptides were conjugated to the
nanoparticles at 1.3x the malemide concentration The
conjugation solution was left for 4 hours and then
collected in RNase-free water.
Experimental Methods cont.
Transfection/Visualization
The conjugated nanoparticles were left to transfect for 6 hours at
37°C. Solution was replaced with RPMI media for 48 hours.
Darmafect 4 was used as a control reagent. Fluorescent and raw
images were taken using a fluorescence microscope.
Results
Nanoparticle Characterization
As indicated by Figure 1, the size of the nanoparticles stay
relatively constant over a period of 7 days and can sustain the
time required to release the nanoparticle’s contents. PLGA and
PLGA-PEG are sufficient materials that can be used for
nanoparticle formulation and sustain the conditions required for
extended drug release without degradation of the polymer. As
shown by Figure 2, the siRNA contained in the nanoparticles is
completely released by 24 hours. This rate of release is faster
than anticipated and bovine serum albumin was later added to
increase the entrapment efficiency as well as to possibly
decrease the rate of release. A fast release rate could contribute
to a significant loss in the available siRNA for gene silencing and
despite the nanoparticles remain stable.
Transfection
Peptide conjugates contained a fluorescent tag to help
visualize the cells. Fluorescence can be observed in the cells
that were transfected using the conjugated nanoparticles. Since
fluorescence was not observed in the controls, this indicates that
a penetrating peptide is required for cellular uptake of PLGA
nanocarriers. The fluorescent images do not indicate which of
the tested peptides is the most effective at cellular penetration.
Functional Assay
GAPDH activity was measured in the cells 42 hours after the
transfection according to the procedure outlined in the Life
technologies GAPDH KDalert Kit. Absorption and fluorescence
were taken on a black plate.
Figure 1. Size stability of siRNA-containing nanoparticles 
over 7 days in 1x PBS
Figure 2. Release rate of siRNA-containing nanoparticles 
over 8 days in 1x PBS at 125RPM at 37°C
Conclusion
The nanoparticles have shown the ability to maintain
physical integrity under in vitro conditions for an
extended period of time in order to release the entire
contents. This allows for modifications to increase the
entrapment efficiency and extend the rate of release for
prolonged drug effects. However, the rapid release rate
observed in this experiment could have potentially
contributed to the lack of gene silencing. A significant
amount of the entrapped siRNA may have been released
during the transfection process outside of the cell
adhering to the outside to produce the fluorescent
images. This would lead to an insufficient amount of
siRNA in the cytoplasm to interact with the RNAi
machinery.
Although fluorescence was observed, this does not
provide any information regarding the release of the
nanoparticle from the endosome, the release of the
siRNA from the nanoparticle, or the RNA interference
activity levels. Nanoparticles may be taken up by natural
endocytosis, however the presence of a peptide
significantly affects the active targeting of the cancer
cells.
The ultimate goal of this project was to optimize
nanoparticle formulation and to test the effectiveness of
these nanoparticles as siRNA delivery vehicles in order
to decrease gene activity. Silencing, however, was not
observed with any of the various nanoparticle
formulations or their deviations.
Future Research
Extensions on this project are currently underway to
optimize the GAPDH functional assay. Further variations
of nanoparticles are being tested with different cell-
penetrating conjugates and formulas in order to increase
entrapment efficiency, improve intercellular release, and
improve potency to produce gene silencing effects.
Additional tests will be conducted to discover if the
nanoparticles are released from the endosomes and the
siRNA strands are released from the nanoparticles.
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Functional Assay
The functional assay was conducted using the same
nanoparticle design. Silencing was observed with commercially
available lipoamine transfection reagents using the same siRNA
strands. There were, however, no observable changes in the
GAPDH activity using the PLGA nanoparticles as the delivery
vehicle. Further modifications also failed to produce any gene
silencing effects.
Nanoparticles Z-average size 
(nm)
Encapsulation 
efficiency
siRNA containing 
NP
164.5 SD ± 5.53 8.11% SD ± 0.62
siRNA x2 NP with 
BSA
173.7 SD ± 1.21 44.35% SD ± 0.20
siRNA x2 NP with 
BSA, CQ, ENX
163.5 SD ± 4.77 N/A
Table 1. Nanoparticle sizes and encapsulation efficiency
TAT CREKA-TAT CREKA-BP16 Unmodified Naked siRNA RPMI Media
Figure 3. Raw and fluorescent microscopy images of transfected MCF-7 cells after 42 hours
